Mutations of the X region of hepatitis B virus and their clinical implications

Pathology International

Volumn 47, Issue 4, 1997, Pages 183-193

  Uchida, Toshikazu ^a   Saitoh, Takafumi ^b   Shinzawa, Haruhide ^b  

^a NIHON UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

hepatitis B virus; mutation; X gene; X protein

Indexed keywords

DOUBLE STRANDED DNA; EPITOPE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; X PROTEIN;

GENE ACTIVATION; GENE DELETION; HEPATITIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; VIRUS EXPRESSION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0030933989     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1997.tb04479.x     Document Type: Review

References (150)

1. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415.
2. Carman WF, Fagan EA, Hadziyannis S et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14: 219-222.
3. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B: Induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-1094.
4. Aye TT, Uchida T, Becker SO et al. Variations of the hepatitis B virus pre-core/core gene sequences in acute and fulminant hepatitis B. Dig. Dis. Sci. 1994; 39:1281-1287.
5. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; ii: 588-590.
6. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyakawa Y, Mayumi M. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J. Virol. 1990; 64:1298-1303.
7. Peters M, Vierling J, Gershwin E, Milich D, Chisari FV, Hoofnagle JH. Immunology and the liver. Hepatology 1991; 13: 977-994.
8. Uchida T. Genetic variations of the hepatitis B virus and their clinical relevance. Microbiol. Immunol. 1993; 37: 425-439.
9. Uchida T, Aye TT, Shikata T et al. Evolution of the hepatitis B virus gene during chronic infection in seven patients. J. Med. Virol. 1994; 43: 148-154.
10. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J. Virol. 1987; 61: 3030-3034.
11. Carman WF, Senate AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; II: 325-329.
12. Okamoto H, Yano K, Nozaki Y et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr. Res. 1992; 32: 264-268.
13. Yamamoto K, Horikita M, Tsuda F et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J. Virol. 1994; 68: 2671-2676.
14. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 1987; 56: 651-693.
15. Schaller H, Fischer M. Transcriptional control of hepadnavirus gene expression. Curr. Top. Microbiol. Immunol. 1991; 168: 21-39.
16. Moriarty AM, Alexander H, Lerner RA. Antibodies to peptides detect new hepatitis B antigen: Serological correlation with hepatocellular carcinoma. Science 1985; 227: 429-432.
17. Suzuki K, Uchida T, Shikata T et al. Expression of pre-S1, pre-S2, S and X peptides in relation to viral replication in livers with chronic hepatitis B. Liver 1990; 10: 355-364.
18. Kay A, Mandart E, Trepo C, Galibert F. The HBV HBx gene expressed in E. coli is recognized by sera from hepatitis patients. EMBO J. 1985; 4: 1287-1292.
19. Siddiqui A, Jameel S, Mapoles J. Expression of the hepatitis B virus X gene in mammalian cells. Proc. Natl Acad. Sci. USA 1987; 84: 2513-2517.
20. Levrero M, Jean-Jean O, Will H, Perricaudet M. Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection. Virology 1990; 74: 299-304.
21. Feitelson MA, Clayton MM. X antigen polypeptide in the sera of hepatitis B virus-infected patients. Virology 1990; 177: 367-371.
22. Feitelson MA, Clayton MM, Blumberg BS. X antigen/antibody markers in hepadnavirus infections. Presence and significance of hepadnavirus X gene product(s) in serum. Gastroenterology 1990; 98: 1071-1078.
23. Horiike N, Blumberg BS, Feitelson MA. Characteristics of hepatitis B X antigen, antibodies to X antigen, and antibodies to the viral polymerase during hepatitis B virus infection. J. Infect. Dis. 1991; 164: 1104-1112.
24. Pfaff E, Salfeld J, Gmelin K, Schaller H, Theilmann L. Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera. Virology 1987; 158: 456-460.
25. Vitvitski-Trepo L, Kay A, Pichoud C et al. Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection. Hepatology 1990; 12: 1278-1283.
26. Kay A, de Dinechin SD, Vitvitski-Trepo L, Mandart E, Shamoon B-M, Galibert F. Recognition of the N-terminal, C-terminal, and interior portions of HBx by sera from patients with hepatitis B. J. Med. Virol. 1991; 33: 228-235.
27. Levrero M, Stemler M, Pasquinelli C et al. Significance of anti-HBx antibodies in hepatitis B virus infection. Hepatology 1991; 13: 143-149.
28. Kwee L, Lucito R, Aufiero B, Schneider RJ. Alternate translation initiation of hepatitis B virus X mRNA produces multiple polypeptides that differentially transactivate class II and III promoters. J. Virol. 1992; 66: 4382-4389.
29. Wollersheim M, Debelka U, Hofschneider PH. A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 1988; 3: 545-552.
30. Takada S, Koike K. Trans-activation function of a 3′ truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc. Natl Acad. Sci. USA 1990; 87: 5628-5632.
31. Nakatake H, Chidaka O, Yamamoto S, Matsubara K, Koshy R. Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication. Virology 1993; 195: 305-314.
32. Spandau DF, Lee C-H. Trans-activation of viral enhancers by the hepatitis B virus X protein. J. Virol. 1966; 62: 427-434.
33. Rossner MT. Hepatitis B virus X-gene product: A promiscuous transcriptional activator. J. Med. Virol. 1992; 36: 101-117.
34. Hu K-Q, Yu C-H, Vierling JM. Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc. Natl Acad. Sci. USA 1992; 89: 11 441-11 445.
35. Zhang P, Raney AK, McLachlan A. Characterization of the hepatitis B virus X- and nucleocapsid gene transcriptional regulatory elements. Virology 1992; 191: 31-41.
36. Avantaggiati ML, Natoli G, Balsano C et al. The hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements. Oncogene 1993; 8: 1567-1574.
37. Menzo S, Clementi M, Alfani E et al. Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology 1993; 196: 878-882.
38. Seto E, Zhou D-X, Peterlin M, Yen TSB. Trans-activation by the hepatitis B virus X protein shows cell-type specificity. Virology 1989; 173: 764-766.
39. Kim C-M, Koike K, Saito I, Miyamura T, Gay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320.
40. Koike K, Moriya K, lino S et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19: 810-819.
41. Robinson WS. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu. Rev. Med. 1994; 45: 297-323.
42. Seto E, Mitchell PJ, Yen TSB. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 1990; 344: 72-74.
43. Linger T, Shaul Y. The X protein of the hepatitis B virus acts as a transcription factor when targeted to its responsive element. EMBO J. 1990; 9: 1889-1895.
44. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991; 252: 842-844.
45. Cross JC, Wen P, Rutter WJ. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc. Natl Acad. Sci. USA 1993; 90: 8078-8082.
46. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumor promoter signaling pathway. Nature 1993; 361: 742-745.
47. Murakami S, Cheong J, Ohno S, Matsushima K, Kaneko S. Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways. Virology 1994; 199: 243-246.
48. Natoli G, Avantaggiati ML, Chirollo P et al. Induction of the DMA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol. Cell. Biol. 1994; 14: 989-998.
49. Takada S, Koike K. X protein of hepatitis B virus resembles a serine protease inhibitor. Jpn. J. Cancer Res. 1990; 81: 1191-1194.
50. Takada S, Kido H, Fukutomi A, Mori T, Koike K. Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor. Oncogene 1994; 9: 341-348.
51. Chirillo P, Falco M, Puri PL et al. Hepatitis B virus pX activates NF-kB-dependent transcription through a raf-independent pathway. J. Virol. 1996; 70: 641-646.
52. De-Medina T, Haviv I, Noiman S, Shaul Y. The X protein of hepatitis B virus has ribo/deoxy ATPase activity. Virology 1994; 202: 401-407.
53. Feitelson MA, Zhu M, Duan L-X, London WT. Hepatitis B x antigen and p53 are associated in vitro and liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8: 1109-1117.
54. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu J-R, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 1994: 91: 2230-2234.
55. Takada S, Tsuchida N, Kobayashi M, Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J. Cancer Res. Clin. Oncol. 1995; 121: 593-601.
56. Jovan RT, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 1995; 69: 1851-1859.
57. Cheong J, Yi M, Lin Y, Murakami S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J. 1995; 14: 143-150.
58. Miller R, Robinson WS. Common evolutionary origin of hepatitis B virus and retroviruses. Proc. Natl Acad. Sci. USA 1986; 83: 2531-2535.
59. Runkel L, Fischer M, Schaller H. Two-codon insertion mutations of the HBx define two separate regions necessary for its transactivation function. Virology 1993; 197: 529-536.
60. Arii M, Takada S, Koike K. Identification of three essential regions of hepatitis B virus X protein for trans-activation function. Oncogene 1992; 7: 397-403.
61. Ritter SE, Whitten TM, Quest AT, Schloemer RH. An internal domain of the hepatitis B virus X antigen is necessary for transactivating activity. Virology 1991; 182: 841-845.
62. Kim Y-H, Kang S-K, Lee Yl. Functional analysis of hepatitis B virus transactivator X: Implication of the leucine zipper-like region and in functional regions. Biochem. Biophys. Res. Commun. 1993; 197: 894-903.
63. Yaginuma K, Shirakata Y, Kobayashi M, Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc. Natl Acad. Sci. USA 1987; 84: 2678-2682.
64. Koike K, Shirakata Y, Yaginuma K et al. Oncogenic potential of hepatitis B virus. Mol. Biol. Med. 1989; 6: 151-160.
65. Blum HE, Zhang Z-S, Galun E et al. Hepatitis B virus X protein is not central to the viral life cycle in vitro. J. Virol. 1992; 66: 1223-1227.
66. Chen H-S, Kaneko S, Girones R et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 1993; 67: 1218-1226.
67. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 1994; 68: 2026-2030.
68. Trujillo MA, Letovsky J, Maguire HF, Lopez-Carbrera M, Siddiqui A. Functional analysis of liver-specific enhancer of the hepatitis B virus. Proc. Natl Acad. Sci. USA 1991; 88: 3797-3801.
69. Nakamura I, Koike K. Identification of a binding protein to the X gene promoter region of hepatitis B virus. Virology 1992; 191: 533-540.
70. Dikstein R, Faktor O, Ben-Levy R, Shaul Y. Functional organization of the hepatitis B virus enhancer. Mol. Cell. Biol. 1990; 10: 3683-3689.
71. Yaginuma K, Nakamura I, Takada S, Koike K. A transcription initiation site for the hepatitis B virus X gene is directed by the promoter-binding protein. J. Virol. 1993; 67: 2559-2565.
72. Takada S, Kaneniwa N, Tsuchida N, Koike K. Hepatitis B virus gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology 1996; 216: 80-89.
73. Reith W, Ucla C, Barras E et al. RFX1, a transactivator of hepatitis B virus enhancer I, belongs to a novel family of homodimeric and heterodimeric DMA-binding proteins. Mol. Cell. Biol. 1994; 14: 1230-1244.
74. Honigwachs J, Faktor O, Dikstein R, Shaul Y, Laub O. Liver-specific expression of hepatitis B virus is determined by the combined action of the core gene promoter and the enhancer. J. Virol. 1989; 63: 919-924.
75. Lopez-Cabrera M, Letovsky J, Hu K-Q, Siddiqui A. Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: Trans-activation and repression by CCAAT/ enhancer binding protein. Proc. Natl Acad. Sci. USA 1990; 87: 5065-5073.
76. Yuh C-H, Chang Y-L, Ting L-P. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J. Virol. 1992; 66: 4073-4084.
77. Yee JK. A liver-specific enhancer in the core promoter region of human hepatitis B virus. Science 1989; 246: 658-661.
78. Lopez-Cabrera M, Letovsky J, Hu K-Z, Siddiqui A. Transcriptional factor C/EBP binds to and transactivates the enhancer element II of the hepatitis B virus. Virology 1991; 183: 825-829.
79. Johnson JL, Raney AK, McLachlan A. Characterization of a functional hepatocyte nuclear factor 3 binding site in the hepatitis B virus nucleocapsid promoter. Virology 1995; 208: 147-158.
80. Hu K-Q, Siddiqui A. Regulation of the hepatitis B virus gene expression by the enhancer element I. Virology 1991; 181: 721-726.
81. Su H, Yee J-K. Regulation of hepatitis B virus gene expression by its two enhancers. PTOC. Natl Acad. Sci. USA 1992; 89: 2708-2712.
82. Lo W-Y, Ting L-P. Repression of enhancer II activity by a negative regulatory element in the hepatitis B virus genome. J. Virol. 1994; 68: 1758-1764.
83. Murakami S, Cheong J, Kaneko S. Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein. J. Biol. Chem. 1994; 269: 15118-15123.
84. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477-484.
85. Wang G-H, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 1993; 67: 6507-6512.
86. Tavis JE, Perri S, Ganem D. Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J. Virol. 1994; 68: 3536-3543.
87. Wang G-H, Zoulim F, Leber EH, Kitson J, Seeger C. Role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J. Virol. 1994; 68: 8437-8442.
88. Pollack JR, Ganem D. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J. Virol. 1994; 68: 5579-5587.
89. Nassal M, Rieger A. A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis. J. Virol. 1996; 70: 2764-2773.
90. Rieger A, Nassal M. Specific hepatitis B virus minus-strand DNA synthesis requires only the 5′ encapsidation signal and the 3′-proximal direct repeat DR1*. J. Virol. 1996; 70: 585-589.
91. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsulation and sufficient for packaging of foreign RNA. EMBO J. 1990; 8: 3389-3396.
92. Will H, Reiser W, Weimer T et al. Replication strategy of human hepatitis B virus. J. Virol. 1987; 61: 904-911.
93. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281: 646-650.
94. Fujiyama A, Miyanohara A, Nozaki C, Yoneyama T, Ohtomo N, Matsubara K. Cloning and structural analysis of hepatitis B virus DNAs, subtype adr. Nucleic Acids Res. 1983; 11: 4601-4610.
95. Ono Y, Onda H, Sasada T, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA: subtype adr and adw. Nucleic Acids Res. 1983; 11: 1747-1757.
96. Kobayashi M, Koike K. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene 1984; 30: 227-232.
97. Bichko V, Pushko P, Drelina D, Pumpen P, Gren E. Subtype ayw variant of hepatitis B virus: DNA primary structure analysis. FEBS Lett. 1985; 185: 208-212.
98. Okamoto H, Imai M, Shimozaki M et al. Nucleotide sequence of a cloned hepatitis B virus genome, subtype ayr: Comparison with genomes of the other three subtypes. J. Gen. Virol. 1986; 67: 2305-2314.
99. Valenzuela P, Quiroga M, Zaldivar J, Gray P, Rutter WJ. The nucleotide sequence of the hepatitis B virus genome and identification of the major viral genes. In: Fields B, Lalnish R, Fox CF, eds. Animal Viral Genetics. Academic Press, New York, 1991; 57-60.
100. Lo SJ, Chien M-L, Lee Y-HW. Characteristics of the X gene of hepatitis B virus. Virology 1988; 167: 289-292.
101. Chen I-H, Huang C-J, Ting L-P. Overlapping initiator and TATA box functions in the basal core promoter of hepatitis B virus. J. Virol. 1995; 69: 3647-3657.
102. Kim SH, Hong SP, Kim SK, Lee WS, Rho HM. Replication of a mutant hepatitis B virus with a fused X-C reading frame in hepatoma cells. J. Gen. Virol. 1992; 73: 2421-2424.
103. Jung M-C, Stemler M, Weimer T et al. Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. Hepatology 1991; 13: 637-643.
104. Stemler M, Weimer T, Tu Z-X et al. Mapping of B-cell epitopes of the human hepatitis B virus X protein. J. Virol. 1990; 64: 2802-2809.
105. Uchida T, Aye TT, Becker SO et al. Detection of precore/coremutant hepatitis B virus genome in patients with acute or fulminant hepatitis without serological markers for recent HBV infection. J. Hepatol. 1993; 18: 369-372.
106. Uchida T, Gotoh K, Shikata T, Tanaka E, Kiyosawa K. 'Silent' hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol. Immunol. 1994; 38: 281-285.
107. Fukuda R, Ishimura N, Kushiyama Y et al. Hepatitis B virus with X gene mutation is associated with the majority of serologically 'silent' non-B, non-C chronic hepatitis. Microbiol. Immunol. 1996; 40: 481-488.
108. Muerhoff AS, Leary TP, Simons JN et al. Genomic organization of GB viruses A and B: Two new members of the Flaviviridae associated with GB agent hepatitis. J. Virol. 1995; 69: 5621-5630.
109. Simons JN, Pilot-Matias TJ, Leary TP et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc. Natl Acad. Sci. USA 1995; 92: 3401-3405.
110. Linnen J, Wages J Jr, Zhang-Keck Z-Y et al. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. Science 1996; 271: 505-508.
111. Uchida T, Aye TT, Shimojima M, Gotoh K, Shikata T. Full-length nucleotide sequence of a hepatitis B virus (HBV) mutant isolated from a patient with acute hepatitis who did not exhibit serological markers for HBV infection. Int. Hepatol. Commun. 1994; 2: 70-73.
112. Uchida T, Gotoh K, Shikata T. Complete nucleotide sequences and the characteristics of two hepatitis B virus mutants causing serological marker-negative acute or chronic hepatitis B. J. Med. Virol. 1994; 45: 247-252.
113. Horikita M, ltoh S, Yamamoto K, Shibayama T, Tsuda F, Okamoto H. Differences in the entire nucleotide sequence between hepatitis B virus genomes from carriers positive for antibody to hepatitis B e antigen with and without active disease. J. Med. Virol. 1994; 44: 96-103.
114. Laskus T, Rakela J, Tong MJ, Nowicki MJ, Mosley JW, Persing DH. Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J. Hepatol. 1994; 20: 837-841.
115. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody e antigen. J. Virol. 1994; 68: 8102-8110.
116. Preisler-Adams S, Schlayer H-J, Peters T, Hettler F, Gerok W, Rasenack J. Sequence analysis of hepatitis B virus DNA in immunologically negative infection. Arch. Virol. 1993; 133: 385-396.
117. Feitelson M, Lega L, Guo J et al. Pathogenesis of posttransfusion viral hepatitis in children with beta-thalassemia. Hepatology 1994; 19: 558-568.
118. Uchida T, Gotoh K, Shikata T, Mima S. Pathology of livers infected with 'silent' hepatitis B virus mutant. Liver 1994; 14: 251-256.
119. Brechot C, Degos F, Lugassy C et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N. Engl. J. Med. 1985; 31: 270-276.
120. Blum HE, Offensperger W-B, Walter E, Offensperger S, Gerok W. Latent hepatitis B virus infection with full-length viral genome in a patient serologically immune to hepatitis B virus infection. Liver 1988; 8: 307-316.
121. Thiers V, Nakajima E, Kremsdorf D et al. Transmission of hepatitis B from hepatitis B-seronegative subjects. Lancet 1988; ii: 1273-1276.
122. Lai ME, Farci P, Figus A, Balestrieri A, Arnone M, Vyas GN. Hepatitis B virus DNA in the serum of Sardinian blood donors negative for the hepatitis B surface antigen. Blood 1989; 73: 17-19.
123. Lai M-Y, Chen P-J, Yang P-M, Sheu J-C, Sung J-L, Chen D-S. Identification and characterization of intrahepatic hepatitis B virus DNA in HBsAg-seronegative patients with chronic liver disease and hepatocellular carcinoma in Taiwan. Hepatology 1990; 12: 575-581.
124. Paterlini P, Gerken G, Nakajima E. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N. Engl. J. Med. 1990; 323: 80-85.
125. Liang TJ, Blum HE, Wands JR. Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology 1990; 12: 204-212.
126. Fagan EA, Davison FD, Trowbridge R et al. Detection of hepatitis B virus DNA sequences in liver in HBsAg seronegative patients with liver disease with and without anti-HBc antibodies. QJM 1991; 78: 123-134.
127. Wright TL, Mamish D, Combs C et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992; I: 952-955.
128. Sardo MA, Rodino G, Brancatelli S et al. Inapparent 'wild-type' and 'e-minus variant' HBV infection in patients with HCV-related chronic hepatitis. Liver 1994; 14: 241-244.
129. Gonzalez S, Navas S, Madejon A et al. Hepatitis B and D genomes in hepatitis B surface antigen negative patients with chronic hepatitis C. J. Med. Virol. 1995; 45: 168-173.
130. Kremsdoft D, Garreau F, Duclos H et al. Complete nucleotide sequence and viral envelope protein expression of a hepatitis B virus DNA derived from a hepatitis B surface antigen-seronegative patient. J. Hepatol. 1993; 18: 244-250.
131. Yuh CH, Chang YL, Ting L-P. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J. Virol. 1992; 66: 4073-4084.
132. Phares W, Herr W. Functional similarities between human immunodeficiency virus type 1 and simian virus 40 kB protoenhancers. J. Virol. 1991; 65: 2200-2210.
133. Steffy K, Weir JP. Mutational analysis of two herpes simplex virus type 1 late promoters. J. Virol. 1991; 65: 6450-6460.
134. Buckwold VE, Xu Z, Chen M, Yen TSB, Ou J-H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 1996; 70: 5845-5851.
135. Ogata N, Miller RH, Ishak KG, Purcell RH. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in champanzees. Virology 1993; 194: 263-276.
136. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J. Virol. 1994; 68: 1651-1659.
137. Hasegawa K, Huang J, Wands JR, Obata H, Uang TJ. Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan. Virology 1991; 185: 460-463.
138. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J. Virol. 1993; 67: 3756-3762.
139. 1764) of hepatitis B virus: Clinical significance and an easy method for detection. J. Gen. Virol. 1995; 76: 3159-3164.
140. Kaneko M, Uchida T, Moriyama M et al. Probable implication of mutations of the X reading frame in the onset of fulminant hepatitis B. J. Med. Virol. 1995; 47: 204-208.
141. Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann. Intern. Med. 1995; 122: 241-248.
142. Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995; 109: 1618-1623.
143. Coursaget P, Yvonnet BY, Bourdil C et al. HBsAg positive reactivity in man not due to hepatitis B virus. Lancet 1987; ii: 1354-1358.
144. Wu J, Ko Y, Lui W. Hepatitis B virus type 2. Lancet 1988; i: 990.
145. Echevarria JM, Leon P, Domingo CJ et al. Characterization of HBV2-like infection in Spain. J. Med. Virol. 1991; 33: 240-247.
146. Repp R, Keller C, Borkhardt A et al. Detection of a hepatitis B virus variant with a truncated X gene and enhancer II. Arch. Virol. 1992; 125: 299-304.
147. Gotoh K, Mima S, Uchida T et al. Nucleotide sequence of hepatitis B virus isolated from subjects with negative serum anti-hepatitis B core. J. Med. Virol. 1995; 46: 201-206.
148. Aye TT, Uchida T, Becker SO, Shikata T, Mima S. Completely or nearly identical hepatitis B virus strains replicate between patients with acute or fulminant hepatitis B and their respective infectious sources. J. Med. Virol. 1994; 42: 60-65.
149. Guo W, Wang J, Tam G, Yen TSB, Ou J. Leaky transcription termination produces larger and smaller than genome size hepatitis B virus X gene transcripts. Virology 1991; 181: 630-636.
150. Hilgar C, Velhagen I, Zentgraf H, Schroder CH. Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma: A novel polyadenylation site on viral DNA. J. Virol. 1991; 65: 4284-4291.